Molecure 将来の成長

Future 基準チェック /26

Molecure利益と収益がそれぞれ年間11.2%と48.4%増加すると予測されています。EPS は年間減少すると予想されています。自己資本利益率は 3 年後に-56.6% 2.8%なると予測されています。

主要情報

11.2%

収益成長率

-2.8%

EPS成長率

Pharmaceuticals 収益成長	15.8%
収益成長率	48.4%
将来の株主資本利益率	-56.6%
アナリストカバレッジ	Low
最終更新日	05 Nov 2024

今後の成長に関する最新情報

Recent updates

Is OncoArendi Therapeutics S.A.'s (WSE:OAT) Shareholder Ownership Skewed Towards Insiders?

Feb 24

Will OncoArendi Therapeutics (WSE:OAT) Spend Its Cash Wisely?

Jan 02

業績と収益の成長予測

WSE:MOC - アナリストの将来予測と過去の財務データ ( )PLN Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	40	-12	N/A	5	2
12/31/2025	63	-17	N/A	16	2
12/31/2024	3	-28	N/A	-25	2
9/30/2024	2	-31	-61	-33	N/A
6/30/2024	2	-30	-67	-29	N/A
3/31/2024	2	-29	-55	-16	N/A
12/31/2023	4	-28	-57	-23	N/A
9/30/2023	9	-45	-53	-40	N/A
6/30/2023	8	-42	-41	-34	N/A
3/31/2023	8	-39	-48	-39	N/A
12/31/2022	8	-36	-44	-34	N/A
9/30/2022	2	-16	-36	-8	N/A
6/30/2022	2	-16	-38	-14	N/A
3/31/2022	2	-15	-37	-15	N/A
12/31/2021	1	-14	-32	-13	N/A
9/30/2021	124	63	63	47	N/A
6/30/2021	124	64	62	47	N/A
3/31/2021	125	67	67	56	N/A
12/31/2020	125	68	66	57	N/A
9/30/2020	2	-3	-31	-2	N/A
6/30/2020	2	-3	-32	-2	N/A
3/31/2020	2	-4	-38	-6	N/A
12/31/2019	2	-4	-42	-7	N/A
9/30/2019	2	-5	-43	-4	N/A
6/30/2019	2	-5	-41	-6	N/A
3/31/2019	1	-5	-36	-4	N/A
12/31/2018	1	-4	-32	-5	N/A
9/30/2018	1	-4	-28	-5	N/A
6/30/2018	2	-4	N/A	-2	N/A
3/31/2018	2	-2	N/A	-2	N/A
12/31/2017	1	-2	N/A	-1	N/A
9/30/2017	1	-3	N/A	-5	N/A
6/30/2017	1	-3	N/A	-4	N/A
3/31/2017	1	-3	N/A	-3	N/A
12/31/2016	1	-2	N/A	-1	N/A
12/31/2015	1	-1	N/A	-2	N/A

アナリストによる今後の成長予測

収入対貯蓄率: MOC今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: MOC今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: MOC今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: MOCの収益 ( 48.4% ) Polish市場 ( 4% ) よりも速いペースで成長すると予測されています。

高い収益成長: MOCの収益 ( 48.4% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: MOC 3 年以内に赤字になると予測されています。

Molecure 将来の成長

Future 基準チェック /26

主要情報

今後の成長に関する最新情報

Price target decreased by 22% to zł23.25

No longer forecast to breakeven

Recent updates

New minor risk - Share price stability

New minor risk - Profitability

Price target decreased by 22% to zł23.25

Second quarter 2024 earnings released: zł0.46 loss per share (vs zł0.29 loss in 2Q 2023)

Is Molecure (WSE:MOC) In A Good Position To Deliver On Growth Plans?

New major risk - Revenue and earnings growth

New minor risk - Financial position

No longer forecast to breakeven

Molecure S.A. Receives Approval to Initiate A Phase II Clinical Trial (KITE) for OATD-01 for the Treatment of Pulmonary Sarcoidosis in Selected Countries of the European Union and Norway

Molecure S.A., Annual General Meeting, Jun 13, 2024

New minor risk - Financial data availability

Is Molecure (WSE:MOC) In A Good Position To Invest In Growth?

Molecure S.A. Announces First Patient in the OATD-01 Phase 2 KITE Study in Pulmonary Sarcoidosis

Molecure S.A. to Report Q3, 2024 Results on Oct 31, 2024

New major risk - Revenue and earnings growth

Molecure S.A Announces No Grant of Permission to Conduct Phase II Clinical Trials for the OATD-01 Molecule I

We're Keeping An Eye On Molecure's (WSE:MOC) Cash Burn Rate

Third quarter 2023 earnings released: zł0.25 loss per share (vs zł0.16 loss in 3Q 2022)

Second quarter 2023 earnings released

New minor risk - Share price stability

New minor risk - Shareholder dilution

Molecure S.A. Receives Clearance from the U.S. Food and Drug Administration on its Investigational New Drug Application to Conduct Phase II Clinical Testing of OATD-01

Molecure S.A. announced that it has received PLN 49.968 million in funding

Is Molecure (WSE:MOC) In A Good Position To Invest In Growth?

Molecure S.A., Annual General Meeting, May 31, 2023

Companies Like Molecure (WSE:MOC) Are In A Position To Invest In Growth

Molecure S.A. to Report Q1, 2023 Results on Apr 28, 2023

Molecure S.A. Announces Management Changes

Molecure S.A. to Begin Clinical Development of Novel Dual Arginase Inhibitor Oatd-02 for the Treatment of Cancer After Gaining Permission to Conduct First Clinical Trial in Poland

Third quarter 2022 earnings released: zł0.16 loss per share (vs zł0.13 loss in 3Q 2021)

Second quarter 2022 earnings released: zł0.27 loss per share (vs zł0.20 loss in 2Q 2021)

Companies Like Molecure (WSE:MOC) Are In A Position To Invest In Growth

Molecure S.A., Annual General Meeting, Jun 30, 2022

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

OncoArendi Therapeutics S.A. Announces Board Appointments

OncoArendi Therapeutics S.A Appoints Samson Fung as Chief Medical Officer

OncoArendi Therapeutics' (WSE:OAT) Earnings Are Weaker Than They Seem

Second quarter 2021 earnings released: zł0.21 loss per share (vs zł0.034 loss in 2Q 2020)

CEO & President of Management Board recently bought zł178k worth of stock

Is OncoArendi Therapeutics S.A.'s (WSE:OAT) Shareholder Ownership Skewed Towards Insiders?

OncoArendi Therapeutics S.A. to Report Q2, 2021 Results on Sep 27, 2021

Will OncoArendi Therapeutics (WSE:OAT) Spend Its Cash Wisely?

New 90-day high: zł57.80

OncoArendi Therapeutics SA and Galapagos Enter into Exclusive Collaboration on Chitinase Inhibitors in Fibrosis

Third quarter 2020 earnings released: zł0.06 loss per share

First half earnings released

New 90-day high - zł19.70

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘